With the development of tumor molecular biology and genomics, it has been recognized that there are great heterogeneity in the biological characteristics, molecular typing and reactivity of the same tumor species among different individuals. In order to achieve true tumor individualized and precise therapy, a new concept of human tumor tissue xenograft model (patient derived tumor xenograft, PDTX) is proposed. The previous study has revealed that PDTX model can truly reflect the biological characteristics of tumor tissue and drug efficacy. And PDTX model could be used to select individual chemotherapy regime, evaluate drug resistance and explore efficacy and safety of new drug. PDTX model has been used in clinical practice of several type of cancer including lung cancer. In this paper, the current research progress of lung cancer PDTX is reviewed.
当前随着肿瘤分子生物学及基因组学的发展，人们已经认识到同一瘤种在不同个体间其生物学特征、分子分型以及对药物干预的反应性都存在巨大的异质性，这种个体化差异是导致肿瘤治疗过程中同病同治而不同效的重要原因，因此为了实现真正的肿瘤个体化精准治疗，肿瘤研究领域提出了一个新的概念即人源肿瘤组织异种移植模型（patient derived tumor xenograft, PDTX）；该模型可以真实地反映患者肿瘤组织的生物学特性以及药物疗效，是研究个体化治疗、药物耐药以及新药研发的重要手段，已被运用包括肺癌在内多个瘤种的临床诊治过程中。本文就当前肺癌PDTX模型的研究进展进行综述。.
Keywords: Lung neoplasms; Patient derived tumor xenograft; Precision therapy.